Tharimmune (NASDAQ:THAR) Trading Down 5.9% – Should You Sell?

by · The Markets Daily

Tharimmune, Inc. (NASDAQ:THAR – Get Free Report)’s stock price fell 5.9% on Thursday . The stock traded as low as $2.20 and last traded at $2.22. 654,343 shares traded hands during trading, an increase of 153% from the average session volume of 258,752 shares. The stock had previously closed at $2.36.

Analyst Upgrades and Downgrades

Several analysts have commented on THAR shares. Wall Street Zen upgraded shares of Tharimmune from a “sell” rating to a “hold” rating in a report on Sunday, October 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tharimmune in a research report on Monday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

View Our Latest Report on THAR

Tharimmune Stock Performance

The company has a market capitalization of $84.54 million, a P/E ratio of -0.58 and a beta of 1.43. The stock’s fifty day moving average price is $2.83 and its 200-day moving average price is $2.56.

Tharimmune (NASDAQ:THAR – Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.09.

Hedge Funds Weigh In On Tharimmune

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new position in Tharimmune in the 2nd quarter valued at about $25,000. Drucker Wealth 3.0 LLC acquired a new stake in Tharimmune during the third quarter worth approximately $29,000. Finally, Franklin Resources Inc. bought a new stake in shares of Tharimmune during the second quarter worth approximately $88,000. 1.16% of the stock is owned by institutional investors.

Tharimmune Company Profile

(Get Free Report)

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.

Further Reading